Ładuje się......
Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial
BACKGROUND: At the time of the initial analysis of overall survival (OS) for the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) randomized, double-blind, phase III trial, approximately 50% of patients had died. A final analysis of OS was subsequently planned for when 75% o...
Zapisane w:
| Główni autorzy: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Oxford University Press
2013
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3906991/ https://ncbi.nlm.nih.gov/pubmed/24317176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djt337 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|